Chemotherapy
Personalized Adaptive Novel Agents for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
PARP Inhibitor
MEDI4736 + Olaparib for Advanced Cancers
Recruiting3 awardsPhase 1 & 2
Newnan, Georgia
This trial is testing a new cancer drug combination to see if it is effective, safe, and has anti-tumor activity. The study will also look at how the drugs are metabolized and how well the combination is tolerated.
Tyrosine Kinase Inhibitor
Targeted Therapy for Advanced Stage Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial is studying how well different targeted drugs work in treating patients with cancer that has progressed after other treatments and has a genomic variant that makes the tumor respond to the drug.
PARP Inhibitor
PARP Inhibitor + CTLA-4 Blockade for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Tampa, Florida
This trial is testing a combination of two drugs to treat ovarian cancer that is caused by a BRCA mutation. The drugs are a PARP inhibitor and a T cell checkpoint inhibitor. The trial is testing to see if this combination is safe and effective.
Angiogenesis Inhibitor
Cediranib + Olaparib for Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing a combination of two drugs to treat patients with solid tumors. Cediranib maleate blocks enzymes needed for cell growth, and olaparib may make the tumor more sensitive to Cediranib maleate.
Popular Filters
Phase 3 Trials
Chemotherapy
Olaparib for Metastatic Breast Cancer
Recruiting2 awardsPhase 3
San Diego, California
This trial will compare the effectiveness and safety of olaparib to standard chemotherapy in treating breast cancer that has spread to other parts of the body and has a mutation in the BRCA1 or BRCA2 gene.
PARP Inhibitor
Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting1 awardPhase 2 & 3
Birmingham, Alabama
This trial is testing two oral drugs, cediranib maleate and olaparib, alone or together, against standard chemotherapy for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous treatments. The drugs aim to block enzymes needed for cancer cell growth. The goal is to see if these drugs are more effective than standard chemotherapy.
PARP Inhibitor
Olaparib vs. Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing two different treatments for ovarian, fallopian tube, or primary peritoneal cancer that has come back. One treatment is a standard chemotherapy treatment, and the other is a new treatment that uses two drugs, olaparib and cediranib maleate. The trial will see if the new treatment is more effective than the standard chemotherapy treatment.
Trials With No Placebo
mTORC1/2 Inhibitor
mTOR/AKT Inhibitors for Endometrial and Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of two different drug combinations in treating patients with recurrent endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer.
Chemotherapy
Olaparib for Metastatic Breast Cancer
Recruiting2 awardsPhase 3
San Diego, California
This trial will compare the effectiveness and safety of olaparib to standard chemotherapy in treating breast cancer that has spread to other parts of the body and has a mutation in the BRCA1 or BRCA2 gene.
PARP Inhibitor
Olaparib + Temozolomide for Sarcoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is testing the safety of an investigational drug combo and what dose is appropriate. The drugs in the combo work by interfering with cancer cells' ability to repair DNA and thus continue dividing.
Angiogenesis Inhibitor
Cediranib + Olaparib for Ovarian and Breast Cancer
Recruiting1 awardPhase 1 & 2
Los Angeles, California
This trial is testing the combination of two drugs, cediranib maleate and olaparib, to treat patients with certain types of recurrent cancer. Cediranib maleate cuts off the blood supply to cancer cells, while olaparib stops them from repairing their DNA. The trial aims to find the best dose and see if the combination works better than using olaparib by itself. Combining cediranib, which cuts off the blood supply to cancer cells, with olaparib, which stops cancer cells from repairing their DNA, may help patients live longer without their cancer getting worse.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.